[1] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2024年版)[J]. 中华肝脏病杂志,2025,33(1):18-33. [2] Zeng Z, Lan T, Wei Y, et al. CCL5/CCR5 axis in human diseases and related treatments[J]. Genes Dis,2022,9(1):12-27. [3] 周华生,周宇,吴巍芸.CXC趋化因子配体14在炎症性疾病中作用的研究进展[J].山东医药,2020,60(25):96-99. [4] Hu L, Zhu Y, Zhang J, et al. Potential circulating biomarkers of circulating chemokines CCL5, MIP-1β and HA as for early detection of cirrhosis related to chronic HBV (hepatitis B virus) infection[J]. BMC Infect Dis,2019,19(1):523. [5] Yang T, Huang L, He J, et al. Establishment of diagnostic model and identification of diagnostic markers between liver cancer and cirrhosis based on multi-chip and machine learning[J]. Clin Exp Pharmacol Physiol,2024,51(8):e13907. [6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年版)[J].中华肝脏病杂志,2022,30(12):1309-1331. [7] 中华医学会肝病学分会.肝硬化诊治指南[J].中华肝脏病杂志,2019,27(11):846-865. [8] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版)[J].中华肝脏病杂志,2019,27(1):18-26. [9] Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers[J]. Gastroenterology,2003,124(1):91-96. [10] 张帆,毛屏,张晨,等.乙肝肝硬化失代偿期并发肝功能衰竭患者血清Autotaxin、Copeptin、LBP与预后的关系研究[J].现代消化及介入诊疗,2024,29(5):534-538. [11] 中国中西医结合学会传染病专业委员会,中国中西医结合学会肝病专业委员会,中华中医药学会肝胆病分会.HBV相关慢加急性肝衰竭中西医结合诊疗推荐意见[J].临床肝胆病杂志,2019,35(6):1215-1221. [12] Zhao X A, Wang J, Chang H, et al. Intrahepatic expression of C-C motif ligand 5 in patients with chronic hepatitis B[J]. Turk J Gastroenterol,2021,32(1):76-81. [13] Xiao P, Li M, Zhou M, et al. TTP protects against acute liver failure by regulating CCL2 and CCL5 through m6A RNA methylation[J]. JCI Insight,2021,6(23):e149276. [14] 黄勇平.趋化因子CCL2、CCL5、CCL7、CCL21和CCL25在肝纤维化和肝硬化病人肝组织中的表达变化[D].广州:南方医科大学,2010. [15] Ambade A, Lowe P, Kodys K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice[J]. Hepatology,2019,69(3):1105-1121. [16] Zhao X, Yin F, Fu L, et al. Garlic-derived exosome-like nanovesicles as a hepatoprotective agent alleviating acute liver failure by inhibiting CCR2/CCR5 signaling and inflammation[J]. Biomater Adv,2023,154:213592. [17] Zhu Z, Jiang H. Identification of oxidative stress-related biomarkers associated with the development of acute-on-chronic liver failure using bioinformatics[J]. Sci Rep,2023,13(1):17073. [18] Xiao Q, Zhao Y, Ma L, et al. Orientin reverses acetaminophen-induced acute liver failure by inhibiting oxidative stress and mitochondrial dysfunction[J]. J Pharmacol Sci,2022,149(1):11-19. [19] Devisme C, Piquet-Pellorce C, Chalin A, et al. CXCL14 chemokine exacerbates acute viral hepatitis in coronavirus MHV-infected mice and is associated with human acute viral hepatitis[J]. FASEB J,2025,39(10):e70591. [20] Li N, Liu H, Xue Y, et al. Targetable Brg1-CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking[J]. EMBO Mol Med,2023,15(3):e16592. [21] Umbaugh D S, Nguyen N T, Smith S H, et al. The p21+ perinecrotic hepatocytes produce the chemokine CXCL14 after a severe acetaminophen overdose promoting hepatocyte injury and delaying regeneration[J]. Toxicology,2024,504:153804. [22] Umbaugh D S, Nguyen N T, Curry S C, et al. The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure[J]. Hepatology,2024,79(6):1352-1364. [23] Liao J, Zhang Z, Yuan Q, et al. A lncRNA Gpr137b-ps/miR-200a-3p/CXCL14 axis modulates hepatic stellate cell (HSC) activation[J]. Toxicol Lett,2021,336:21-31. |